Development of Recombinant Adeno-Associated Virus Serotype 2/8 Carrying Kringle Domains of Human Plasminogen for Sustained Expression and Cancer Therapy

Human Gene Therapy

Volumn 26, Issue 9, 2015, Pages 603-613

  Kuo, Cheng Hsiang ^a   Chang, Bi Ing ^a,b   Lee, Fang Tzu ^a,b   Chen, Po Ku ^a   Lee, Jeng Shin ^c   Shi, Guey Yueh ^a,b   Wu, Hua Lin ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOSTATIN; K15TM PROTEIN; PARVOVIRUS VECTOR; PLASMINOGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 8; AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSDUCTION; KRINGLE DOMAIN; LEWIS CARCINOMA; LUNG METASTASIS; MALE; MELANOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; STABLE EXPRESSION; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS RECOMBINANT; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; CARCINOMA, LEWIS LUNG; DEPENDOPARVOVIRUS; GENE EXPRESSION; GENE THERAPY; GENETICS; HEK293 CELL LINE; HUMAN; LUNG NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); NONOBESE DIABETIC MOUSE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; SCID MOUSE; SECONDARY;

ANIMALS; APOPTOSIS; CARCINOMA, LEWIS LUNG; DEPENDOVIRUS; GENE EXPRESSION; GENETIC THERAPY; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMINOGEN; PROTEIN STRUCTURE, TERTIARY;

EID: 84941270907     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.220     Document Type: Article

References (36)

1. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18.
2. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456-1463.
3. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007;6: 273-286.
4. Ribatti D. Endogenous inhibitors of angiogenesis: a historical review. Leuk Res 2009;33:638-644.
5. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328.
6. Beerepoot LV, Witteveen EO, Groenewegen G, et al. Recombinant human angiostatin by twicedaily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study. Clin Cancer Res 2003;9:4025-4033.
7. Kurup A, Lin C, Murry DJ, et al. Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. Ann Oncol 2006;17: 97-103.
8. Mowery YM, Pizzo SV. The antitumorigenic trifecta. Blood 2009;114:1727-1728.
9. Lee TY, Tjin Tham Sjin RM, Movahedi S, et al. Linking antibody Fc domain to endostatin significantly improves endostatin half-life and efficacy. Clin Cancer Res 2008;14:1487-1493.
10. Cao Y, O'Reilly MS, Marshall B, et al. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest 1998;101:1055-1063.
11. Chang PC, Chang YJ, Wu HL, et al. Mutation of human plasminogen kringle 1-5 enhances antiangiogenic action via increased interaction with integrin avb3. Thromb Haemost 2008;99:729-738.
12. Jullienne B, Vigant F, Muth E, et al. Efficient delivery of angiostatin K1-5 into tumors following insertion of an NGR peptide into adenovirus capsid. Gene Ther 2009;16:1405-1415.
13. Lee TY, Muschal S, Pravda EA, et al. Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 2009;114:1987-1998.
14. Luo WY, Shih YS, Hung CL, et al. Development of the hybrid Sleeping Beauty: baculovirus vector for sustained gene expression and cancer therapy. Gene Ther 2012;19:844-851.
15. Ponnazhagan S, Mahendra G, Kumar S, et al. Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector encoding angiostatin and endostatin over vectors encoding a single factor. Cancer Res 2004; 64:1781-1787.
16. Torimura T, Ueno T, Sata M. Liposome-mediated gene transfer of K1-5 suppresses tumor development and improves the prognosis of hepatocellular carcinoma in mice. Med Mol Morphol 2006;39:72-78.
17. Cao R, Wu HL, Veitonmaki N, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci USA 1999;96: 5728-5733.
18. Kay MA. State-of-the-art gene-based therapies: the road ahead. Nat Rev Genet 2011;12:316-328.
19. Samaranayake H, Maatta AM, Pikkarainen J, et al. Future prospects and challenges of antiangiogenic cancer gene therapy. Hum Gene Ther 2010;21:381-396.
20. Heilbronn R, Weger S. Viral vectors for gene transfer: current status of gene therapeutics. Handb Exp Pharmacol 2010;197:143-170.
21. Kuo CH, Chen PK, Chang BI, et al. The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. Blood 2012;119:1302-1313.
22. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998;72: 2224-2232.
23. Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-221.
24. Kaeppel C, Beattie SG, Fronza R, et al. A largely random AAV integration profile after LPLD gene therapy. Nat Med 2013;19:889-891.
25. Park K, Kim WJ, Cho YH, et al. Cancer gene therapy using adeno-associated virus vectors. Front Biosci 2008;13:2653-2659.
26. Nathwani AC, Rosales C, Mcintosh J, et al. Longterm safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 2011;19:876-885.
27. Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365: 2357-2365.
28. Sanchez CE, Tierney TS, Gale JT, et al. Recombinant adeno-associated virus type 2 pseudotypes: comparing safety, specificity, and transduction efficiency in the primate striatum: laboratory investigation. J Neurosurg 2011;114: 672-680.
29. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008;15:858-863.
30. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12:342-347.
31. Gao GP, Alvira MR, Wang L, et al. Novel adenoassociated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002;99:11854-11859.
32. Nakai H, Fuess S, Storm TA, et al. Unrestricted hepatocyte transduction with adeno-associated virus serotype 8 vectors in mice. J Virol 2005;79: 214-224.
33. Vanrell L, Di Scala M, Blanco L, et al. Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther 2011;19:1245-1253.
34. Aalbers CJ, Tak PP, Vervoordeldonk MJ. Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon. F1000 Med Rep 2011;3:17.
35. Flannery JG, Visel M. Adeno-associated viral vectors for gene therapy of inherited retinal degenerations. Methods Mol Biol 2013;935:351-369.
36. Lalani AS, Chang B, Lin J, et al. Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy. Mol Ther 2004;9:56-66.